Orexin-A Levels in Non-Alcoholic Fatty Liver Disease: A Case- Control Study Exploring Metabolic and Hepatic Correlations | ||||
| Ain Shams Medical Journal | ||||
| Volume 76, Issue 2, June 2025, Page 420-428 PDF (463.83 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/asmj.2025.358987.1385 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed Mohamed Naguib  ; Hend Abdelwahab Mohamed; Mohamed Marie Makhlouf; Ahmed Abbas Abdo
| ||||
| Department of Internal Medicine, Ain Shams University | ||||
| Abstract | ||||
| Background: Nonalcoholic fatty liver disease (NAFLD) is a global health concern, closely associated with obesity, type 2 diabetes mellitus (T2DM) and dyslipidemia. Orexin-A, a neuropeptide involved in metabolic regulation, has been implicated in NAFLD pathophysiology. Aim of the work: To assess peripheral Orexin-A levels in NAFLD patients and their correlation with metabolic risk factors. Patients and Methods: This case-control study included 45 participants: 15 NAFLD patients without diabetes (Group 1), 15 NAFLD patients with diabetes (Group 2), and 15 healthy controls (Group 3). Lipid profile, HbA1c, and NAFLD fibrosis score (NFS) were analyzed. A Sandwich ELISA assay was employed to determine serum Orexin-A levels. Results: NAFLD patients exhibited significantly lower Orexin-A levels compared to controls (0.34 vs. 2.12 pg/mL, P < 0.001). Orexin-A correlated negatively with serum albumin (r = -0.361, P = 0.05) and blood urea in diabetic NAFLD patients (r = -0.612, P = 0.015). ROC analysis demonstrated that Orexin-A ≤0.66 pg/mL effectively differentiated NAFLD patients from controls (AUC = 0.877, sensitivity = 90%, specificity = 86.67%). Conclusion: Orexin-A is significantly reduced in NAFLD patients, suggesting its potential role as a biomarker for NAFLD detection and disease severity assessment. | ||||
| Keywords | ||||
| Metabolic syndrome; NAFLD; orexin-A; type 2 diabetes mellitus | ||||
|
Statistics Article View: 4 PDF Download: 3 |
||||
